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Abstract
Background: Current prophylactic vaccines against human papillomavirus (HPV) target two of the most oncogenic types,
HPV-16 and -18, which contribute to roughly 70% of cervical cancers worldwide. Second-generation HPV vaccines include a
9-valent vaccine, which targets five additional oncogenic HPV types (i.e., 31, 33, 45, 52, and 58) that contribute to another
15–30% of cervical cancer cases. The objective of this study was to determine a range of vaccine costs for which the 9-valent
vaccine would be cost-effective in comparison to the current vaccines in two less developed countries (i.e., Kenya and
Uganda).
Methods and Findings: The analysis was performed using a natural history disease simulation model of HPV and cervical
cancer. The mathematical model simulates individual women from an early age and tracks health events and resource use
as they transition through clinically-relevant health states over their lifetime. Epidemiological data on HPV prevalence and
cancer incidence were used to adapt the model to Kenya and Uganda. Health benefit, or effectiveness, from HPV
vaccination was measured in terms of life expectancy, and costs were measured in international dollars (I$). The incremental
cost of the 9-valent vaccine included the added cost of the vaccine counterbalanced by costs averted from additional
cancer cases prevented. All future costs and health benefits were discounted at an annual rate of 3% in the base case
analysis. We conducted sensitivity analyses to investigate how infection with multiple HPV types, unidentifiable HPV types
in cancer cases, and cross-protection against non-vaccine types could affect the potential cost range of the 9-valent vaccine.
In the base case analysis in Kenya, we found that vaccination with the 9-valent vaccine was very cost-effective (i.e., had an
incremental cost-effectiveness ratio below per-capita GDP), compared to the current vaccines provided the added cost of
the 9-valent vaccine did not exceed I$9.7 per vaccinated girl. To be considered very cost-effective, the added cost per
vaccinated girl could go up to I$5.2 and I$16.2 in the worst-case and best-case scenarios, respectively. At a willingness-to-
pay threshold of three times per-capita GDP where the 9-valent vaccine would be considered cost-effective, the thresholds
of added costs associated with the 9-valent vaccine were I$27.3, I$14.5 and I$45.3 per vaccinated girl for the base case,
worst-case and best-case scenarios, respectively. In Uganda, vaccination with the 9-valent vaccine was very cost-effective
when the added cost of the 9-valent vaccine did not exceed I$8.3 per vaccinated girl. To be considered very cost-effective,
the added cost per vaccinated girl could go up to I$4.5 and I$13.7 in the worst-case and best-case scenarios, respectively. At
a willingness-to-pay threshold of three times per-capita GDP, the thresholds of added costs associated with the 9-valent
vaccine were I$23.4, I$12.6 and I$38.4 per vaccinated girl for the base case, worst-case and best-case scenarios, respectively.
Conclusions: This study provides a threshold range of incremental costs associated with the 9-valent HPV vaccine that
would make it a cost-effective intervention in comparison to currently available HPV vaccines in Kenya and Uganda. These
prices represent a 71% and 61% increase over the price offered to the GAVI Alliance ($5 per dose) for the currently available
2- and 4-valent vaccines in Kenya and Uganda, respectively. Despite evidence of cost-effectiveness, critical challenges
around affordability and feasibility of HPV vaccination and other competing needs in low-resource settings such as Kenya
and Uganda remain.
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Prophylactic vaccines against human papillomavirus (HPV)
represent a major breakthrough in cancer prevention. Two
available HPV vaccines target two of the most oncogenic types,
HPV-16 and -18, that contribute to roughly 70% of cervical
cancers – and a smaller proportion of other anogenital and oral
cancers – worldwide [1]; one of these vaccines also targets non-
oncogenic types, HPV-6 and -11, which cause the majority of
genital warts. Second-generation HPV vaccines include a 9-valent
(‘‘nonavalent’’) vaccine, which targets five additional oncogenic
HPV types (i.e., 31, 33, 45, 52, and 58) that contribute to another
15–30% of cervical cancer cases [2]. Merck & Co., Inc.
announced in November 2013 that its investigational 9-valent
HPV vaccine (V503) prevented approximately 97% of cervical,
vaginal and vulvar pre-cancers caused by HPV types 31, 33, 45,
52, and 58 in a Phase III efficacy study. The new vaccine also
generated non-inferior immune responses to HPV types 6, 11, 16,
and 18 compared with those generated by the current 4-valent
HPV vaccine [3,4].
In a previous model-based analysis, under similar efficacy
assumptions, we demonstrated that the 9-valent vaccine yields
greater reductions in cervical cancer, compared to currently-
available 2- and 4-valent vaccines [5]. We explored several
uncertainties with respect to HPV infections and vaccine
properties and found that the prevalence of co-infection with
multiple HPV types and unidentifiable HPV types in cancer cases
can influence estimates of vaccine effectiveness, but that the
magnitude of effect may be moderated by vaccine cross-protection
against HPV types not targeted by the vaccine [5]. For countries
considering adoption of HPV vaccination, information on how the
added benefit of the 9-valent vaccine weighs against its cost will be
critical.
This report is intended as a follow-up to the previous analysis of
the population-level health effects of HPV vaccination with the 9-
valent vaccine in Kenya and Uganda [5] and focuses on
determining a range of vaccine costs for which the 9-valent
vaccine would be cost-effective in comparison to the current HPV
vaccines. As in our previous analysis [5], we explored the
influences of co-infection with multiple HPV types, unidentifiable
HPV types, and cross-protection against non-targeted HPV types
on the cost thresholds of the 9-valent vaccine.
Methods
The analysis was performed in the context of two separate
countries, Kenya and Uganda, using a natural history disease
simulation model of HPV and cervical cancer. The mathematical
model simulates individual women from an early age (age 9) and
tracks health events and resource use as they transition through
clinically-relevant health states over their lifetime (Figure 1). We
performed the analysis based on a single cohort of 1,000,000
preadolescent girls in Kenya and in Uganda. The disease
simulation model used in this study was a static (non-dynamic)
stochastic model. Therefore, this model did not account for herd-
immunity effects.
Epidemiological data on HPV prevalence and cancer incidence
were used to adapt the model to each country in a calibration
process that has been described in previous publications [5,6]. In
brief, the model calibration was performed in two steps. In the first
step, primary epidemiologic data were used to identify a plausible
range for each natural history input parameter. In the second step,
a simultaneous search over all input parameters was performed to
identify parameter sets that produced outputs consistent with
empirical calibration target data. The calibrated model had
reasonable fit to the empirical target data with respect to duration
and prevalence of high-risk HPV infections, prevalence of
precancerous lesions, and incidence of cervical cancer. A complete
description of the model and a complete description of the model
calibration process were previously reported [7]. Kenya and
Uganda were selected because of the range in contribution of
HPV-16 and -18 in cervical cancer cases, 62.2% and 73.9%
respectively [2], as well as the absence of organized cervical cancer
screening programs.
In the current analysis, we used the model to determine a
potential cost range of the 9-valent vaccine that would make it
cost-effective in comparison to the current HPV vaccines in Kenya
and Uganda. Cost-effectiveness was expressed in terms of the
incremental cost-effectiveness ratio, defined as the additional cost
of the 9-valent vaccine divided by the additional health benefit,
compared to the current (2- or 4-valent) vaccines. We assumed
that HPV vaccination occurred in pre-adolescence (by age 12)
prior to sexual debut, and coverage for all three required doses was
100% for any of the HPV vaccines. We assumed 100% vaccine
efficacy against targeted HPV types over the lifetime for both
currently available vaccines and the 9-valent vaccine as in
previously published studies [5,6]. Health benefit, or effectiveness,
from HPV vaccination was measured in terms of life expectancy,
and costs were measured in 2005 international dollars (I$) to make
the analysis consistent with and comparable to a previously
published study [6]. The incremental cost of the 9-valent vaccine
included the added cost of the vaccine counterbalanced by costs
averted from additional cancer cases prevented. Direct medical
costs associated with diagnosis and treatment of cervical cancers
included the facility visits, personnel, procedures (including
pharmaceuticals and supplies), and cancer care (including staging
of cancer severity, hospitalizations, stage-appropriate treatments).
Consistent with the societal perspective, we also included the cost
of patient transport and time spent traveling, waiting, and
receiving care [6,8]. All future costs and health benefits were
discounted at an annual rate of 3% in the base case analysis.
There is no universally-accepted criterion that defines a
threshold cost-effectiveness ratio below which a technology or
intervention would be considered good value for money. We
followed the Commission on Macroeconomics and Health’s
suggestion that interventions with a cost-effectiveness ratio less
than a country’s Gross Domestic Product (GDP) per capita could
be considered ‘‘very cost-effective’’ and less than three times the
GDP per capita could be considered ‘‘cost-effective’’ [9]. Using
these two levels of GDP as proxies for societal willingness-to-pay
for a year of life saved, we calculated the cost threshold of the
Figure 1. Disease simulation model of HPV and cervical cancer.
The model comprises mutually-exclusive and collectively-exhaustive
health states that represent key elements of HPV infection and cervical
carcinogenesis. Individual women are simulated in the model from an
early age (age 9) and transition through these health states over the
lifetime. Health events, outcomes, and resource use are tracked and
aggregated at the population level.
doi:10.1371/journal.pone.0106836.g001
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vaccine would be (very) cost-effective, compared to vaccination
with the 2- or 4-valent vaccines. The GDP per capita in 2005 for
Kenya was I$1470 and for Uganda was I$1077 [10].
Analyses were conducted under three different scenarios as
described in detail in a previous study [5]. Briefly, in Scenario A,
there is assumed to be no overlap between unidentifiable HPV
types and multiple infections with HPV types that are targeted by
the 9-valent vaccine, and therefore, the 9-valent vaccine does not
offer any benefit in preventing these cases. For Scenario B, there is
some overlap between unidentifiable HPV types and multiple
infections with vaccine-targeted HPV types, and therefore, the 9-
valent vaccine has the ability to prevent some of these cases,
proportional to the prevalence of the five targeted HPV types
relative to the prevalence of all non-16/18 types. For Scenario C,
there is complete overlap between unidentifiable HPV types and
multiple infections with vaccine-targeted HPV types, and there-
fore, the 9-valent vaccine offers full protective benefits in
preventing these cases. Four possible levels of cross-protective
effects (0%, 7.4%, 37.4% and 58.2%) against non-vaccine types
based on vaccine trial data were incorporated into Scenarios A, B
and C [11]. For the base case analysis, we selected scenario B, in
which the 9-valent vaccine has the ability to prevent some cases
with unidentifiable types and multiple infections, in conjunction
with a moderate level of cross-protective effects against non-
vaccine types (37.4%). One-way sensitivity analysis was performed
to evaluate the effects of each source of uncertainty on the 9-valent
vaccine cost threshold. Two-way sensitivity analysis and best- and
worst-case scenarios were conducted to evaluate the simultaneous
effects of multiple sources of uncertainties on the potential cost
range. The most optimistic scenario for the incremental benefits of
the 9-valent vaccine is if it can fully protect against unidentifiable
HPV types and multiple infections (Scenario C), while also
assuming that none of the vaccines (both the 9-valent vaccine and
current vaccines) provide cross-protection against non-vaccine
HPV types. The least optimistic scenario is if cases with
unidentifiable types and multiple infections are not attributable
to the additional types targeted by the 9-valent vaccine (Scenario
A) while also assuming that all the vaccines provide high cross-
protection against non-vaccine types. A sensitivity analysis on the
discounting rate was performed to explore the effects of time
preference on the vaccine cost threshold.
Results
Table 1 shows the cost thresholds of the 9-valent HPV vaccine
at which the incremental cost-effectiveness ratio of HPV
vaccination with the 9-valent vaccine versus the 2- or 4-valent
vaccine is equal to per-capita GDP and three times per-capita
GDP under various scenarios. In the base case analysis in Kenya,
vaccination with the 9-valent vaccine was very cost-effective (i.e.,
had an incremental cost-effectiveness ratio below per-capita GDP),
compared to the current vaccines provided the added cost of the 9-
valent vaccine did not exceed I$9.7 per vaccinated girl. In the
worst-case scenario in which the 9-valent could not protect against
any unidentifiable HPV types and multiple infections (Scenario A)
with an assumption that the vaccines (both the 9-valent vaccine
and current vaccines) provide high cross-protection against non-
vaccine HPV types, this cost threshold decreased to I$5.2 per
vaccinated girl. In the best-case scenario in which the 9-valent
vaccine could fully protect against unidentifiable HPV types and
Table 1. Thresholds of incremental cost (I$) per vaccinated girl associated with the 9-valent vaccine in Kenya and Uganda
(discounting rate =3% per year)*.
Kenya Uganda
Willingness-to-pay thresholds
1x GDP per
capita
3x GDP per
capita
1x GDP per
capita
3x GDP per
capita
Base case scenario
{
9.7 27.3 8.3 23.4
One-way sensitivity analysis on multiple HPV infections & unidentifiable types
No benefit to prevent cervical cancer with unidentifiable types and multiple infections 7.4 20.7 6.5 18.4
Full benefit to prevent cervical cancer with unidentifiable types and multiple infections 10.8 30.4 9.1 25.5
One-way sensitivity analysis on cross-protective effects against non-vaccine types
0% cross-protective effects 14.5 40.6 12.5 35.2
7.4% cross-protective effects 13.6 38.1 11.7 33.0
58.2% cross-protective effects 6.8 19.1 5.8 16.2
Two-way sensitivity analysis on multiple infections & unidentifiable types and
cross-protective effects
No benefit to prevent cervical cancer with unidentifiable types and multiple infections
with 58.2% cross-protective effects
5.2 14.5 4.5 12.6
Full benefit to prevent cervical cancer with unidentifiable types and multiple infections
with no cross-protective effects
16.2 45.3 13.7 38.4
* GDP = gross domestic product; I$ = international dollars. Values represent the added cost of the 9-valent HPV vaccine at which the incremental cost-effectiveness
ratio (compared to current 2- or 4-valent vaccines) would be equal to 1x or 3x per capita GDP in each country.
{ Base case scenario = some benefits to prevent cervical cancer with unidentifiable types and multiple infections, defined as a function of the prevalence of the five
targeted HPV types relative to the prevalence of all non-16/18 types, with 37.4% cross-protection against non-vaccine types.
doi:10.1371/journal.pone.0106836.t001
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protection against non-vaccine HPV types, the added costs of the
9-valent vaccine could increase to I$16.2 per vaccinated girl. At a
willingness-to-pay threshold of three times per-capita GDP, the
thresholds of added costs associated with the 9-valent vaccine were
I$27.3, I$14.5 and I$45.3 per vaccinated girl for the base case,
worst-case and best-case scenarios, respectively.
In Uganda, the threshold cost of the 9-valent vaccine over the 2-
or 4-valent vaccines was found to be lower than in Kenya across
all scenarios. For example, in the base case analysis, the cost
threshold for the 9-valent vaccine was I$8.3 and I$23.4 per
vaccinated girl when the willingness-to-pay threshold was one time
and three times per-capita GDP, respectively. From the worst-case
to best-case scenarios, the threshold cost associated with the 9-
valent vaccine ranged from I$4.5 to I$13.7 per vaccinated girl,
assuming a willingness-to-pay threshold of per-capita GDP, and
I$12.6 to I$38.4 per vaccinated girl, assuming a willingness-to-pay
threshold of three times per-capita GDP.
Table 2 shows the impact of varying time preference on the
threshold costs. With a discounting rate of 0%, the threshold cost
per vaccinated girl of the 9-valent vaccine could increase from
I$9.7 to I$50.4 in Kenya and from I$8.3 to I$41.3 in Uganda.
With a discounting rate of 5% per year, the threshold cost per
vaccinated girl of the 9-valent vaccine could decrease from I$9.7 to
I$3.6 in Kenya and from I$8.3 to I$3.2 in Uganda.
Discussion
This analysis estimates a range of added vaccine costs within
which HPV vaccination with the 9-valent vaccine remains cost-
effective compared to vaccination with current (2- or 4-valent)
vaccines in Kenya and Uganda. Because of the added health
benefits from vaccination with the 9-valent vaccine, we expected
that additional costs could be incurred with the 9-valent vaccine
compared to the current vaccines. We found that co-infection with
multiple HPV types, unidentifiable HPV types, and cross-
protection against non-vaccine types all influenced the potential
cost range of the 9-valent vaccine. Results were also quite sensitive
to the annual rate at which future costs and benefits were
discounted since the health benefits of cancers averted are
expected to be realized long after the upfront cost of vaccination
is incurred. The discount rate will play an important role when
comparing the HPV vaccines with other vaccines or health
interventions that return more immediate health impact.
Despite the utility of our disease simulation model in projecting
incremental cost thresholds of the 9-valent vaccine under complex
interactions of various uncertainties, our model and analysis have
limitations. First of all, our disease simulation model is not a
dynamic model and therefore is not able to capture herd-
immunity effects. However, with the assumption that there were
perfect vaccine uptake and dosage completion, herd-immunity
effects would have little or no influence on the findings. Secondly,
we did not vary the levels of vaccine uptake and completion.
Perfect vaccine uptake is unlikely even in developed countries;
however, by assuming complete coverage, we were able to
estimate the maximum incremental cost thresholds of the 9-valent
vaccine under the different scenarios.
If we consider only the current 2- or 4-valent HPV vaccines in
Kenya and Uganda, the cost per vaccinated girl should not exceed
I$41.6 and I$62.5,respectively (comparedto no HPVvaccination at
all) to remain below a willingness-to-pay threshold of 1x per-capita
GDP. At a higher willingness-to-pay threshold of 3x per-capita
GDP, the cost per vaccinated girl with current 2- or 4-valent HPV
vaccines in Kenya and Uganda (compared to no vaccination at all)
Table 2. Impact of discount rate on thresholds of incremental cost (I$) per vaccinated girl associated with the 9-valent vaccine*.
Kenya Uganda
Annual discount rate
0% 5% 0% 5%
Base case scenario
{
50.4 3.6 41.3 3.2
One-way sensitivity analysis on multiple HPV infections & unidentifiable types
No benefit to prevent cervical cancer with unidentifiable types and multiple
infections
38.3 2.7 32.4 2.5
Full benefit to prevent cervical cancer with unidentifiable types and multiple
infections
55.9 4.0 44.9 3.4
One-way sensitivity analysis on cross-protective effects against non-vaccine types
0% cross-protective effects 75.1 5.3 62.1 4.7
7.4% cross-protective effects 70.4 5.0 58.2 4.4
58.2% cross-protective effects 34.9 2.5 28.3 2.2
Two-way sensitivity analysis on multiple infections & unidentifiable types and cross-protective effects
No benefit to prevent cervical cancer with unidentifiable types and multiple
infections with 58.2% cross-protective effects
26.7 1.9 22.1 1.7
Full benefit to prevent cervical cancer with unidentifiable types and multiple
infections with no cross-protective effects
83.7 6.0 67.7 5.2
* GDP = gross domestic product; I$ = international dollars. Values represent the added cost of the 9-valent HPV vaccine at which the incremental cost-effectiveness
ratio (compared to current 2- or 4-valent vaccines) would be equal to 1x per capita GDP in each country.
{ Base case scenario = some benefits to prevent cervical cancer with unidentifiable types and multiple infections, defined as a function of the prevalence of the five
targeted HPV types relative to the prevalence of all non-16/18 types, with 37.4% cross-protection against non-vaccine types.
doi:10.1371/journal.pone.0106836.t002
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File S1).
The presumed additional benefit of the 9-valent vaccine is also
expected to come at a higher cost, primarily attributed to a higher
price of the vaccine doses compared to current vaccines, since both
generations of vaccines are expected to have the same delivery
requirements and dosing schedule and will require similar
resources, such as healthcare providers, vaccine storage, and
supply chain facilities. We found that at a threshold willingness-to-
pay of per-capita GDP, the incremental cost per vaccinated girl of
the 9-valent HPV vaccine should be no more than I$9.7 in Kenya
and I$8.3 in Uganda, implying an additional I$3.2 per dose and
I$2.8 per dose, respectively. At a higher willingness-to-pay
threshold of three times per-capita GDP, the incremental cost of
the 9-valent vaccine should be no more than I$9.1 per dose in
Kenya and I$7.8 per dose in Uganda, compared to current
vaccines. Note that we focused our analysis on vaccine benefit to
cervical cancer cases. The cost estimates do not reflect vaccine
benefit to other non-cervical HPV related diseases. HPV-related
non-cervical cancer cases are predominantly attributable to HPV
type 16 which is already targeted by currently available vaccines
[12]. As a result, we would not expect the 9-valent vaccine to yield
much more additional benefit to non-cervical cancer cases.
Unprecedented low prices of $4.5 per dose for Merck’s Gardasil
(4-valent) vaccine and $4.6 per dose for GlaxoSmithKline’s
Cervarix (2-valent) vaccine have recently been negotiated through
the GAVI Alliance, a public-private alliance dedicated to
facilitating access to immunization programs in the poorest
countries [13]. Both Kenya and Uganda are eligible to apply for
GAVI Alliance support for HPV vaccination, and in May 2013,
Kenya became the first country of seven sub-Saharan African
countries to win support from the GAVI Alliance to initiate an
HPV vaccination program for girls [14]. It is uncertain how much
higher the manufacturer will price the 9-valent vaccine compared
to current vaccines. Also, it is uncertain whether the GAVI
Alliance will be able to successfully negotiate the price of the 9-
valent vaccine as it did for the current vaccines. An additional
I$3.2 per dose in Kenya and I$2.8 per dose in Uganda for the 9-
valent vaccine (assuming a cost-effectiveness threshold of per-
capita GDP) represent a 71% and 61% increase over the price
offered to the GAVI Alliance for the currently available vaccines
in Kenya and Uganda, respectively. At these prices, HPV
vaccination of a single cohort of 12-year old girls with the 9-
valent vaccine instead of the current vaccines at 100% coverage in
Kenya (460,640 girls) and in Uganda (459,066 girls) [15] would
require additional costs of approximately I$4.5 million in Kenya
and I$3.8 million in Uganda per year.
In addition to assessments of value for money, a policy maker
will need to carefully consider the financial burden and competing
health needs, especially in resource-poor settings such as Kenya
and Uganda. Specifically, in low-resource settings such as Kenya
and Uganda, willingness-to-pay thresholds of 1x per-capita GDP
and 3x per-capita GDP can be useful in guiding policy decisions
whether to adopt new vaccines or other health interventions but
should not be the only information considered. Policy makers
should also consider the availability of other public programs (e.g.,
education, housing and water sanitation) and compare their costs
and benefits in order to make appropriate resource allocations.
Policy makers might find that other public programs are much
more in need and are more cost-effective compared to a new HPV
vaccination program. Importantly, the 9-valent HPV vaccine will
need to be assessed for its feasibility, sustainability, acceptability,
and competing needs based on country-specific contexts.
In summary, this study provides a threshold range of
incremental costs associated with the 9-valent HPV vaccine that
would make it a cost-effective intervention in comparison to
currently available HPV vaccines in Kenya and Uganda. At a
willingness-to-pay threshold of per-capita GDP, the added cost for
the 9-valent vaccine should be no more than I$3.2 and I$2.8 per
dose compared to current HPV vaccines in Kenya and Uganda,
respectively. At a higher willingness-to-pay of three times per-
capita GDP, the 9-valent vaccine should cost no more than I$9.1
and I$7.8 per dose in Kenya and Uganda, respectively. Despite
evidence of cost-effectiveness, critical challenges around afford-
ability and feasibility of HPV vaccination in settings such as Kenya
and Uganda remain.
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